The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 01, 2020

Filed:

Dec. 16, 2016
Applicants:

Link Genomics, Inc., Tokyo, JP;

Rohto Pharmaceutical Co., Ltd., Osaka, JP;

Inventors:

Shinichiro Niwa, Tokyo, JP;

Dai Ogura, Tokyo, JP;

Hidemi Mizunuma, Tokyo, JP;

Yoko Arai, Tokyo, JP;

Takahiro Kurose, Osaka, JP;

Yoshihiro Takai, Osaka, JP;

Yoko Mitsuguchi, Osaka, JP;

Mariyo Moriya, Osaka, JP;

Assignees:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/50 (2006.01); A61K 31/436 (2006.01); A61K 31/192 (2006.01); A61K 31/38 (2006.01); A61K 31/404 (2006.01); A61K 31/421 (2006.01); A61K 31/426 (2006.01); A61K 31/47 (2006.01); A61K 31/41 (2006.01); A61K 45/00 (2006.01); A61P 27/02 (2006.01); A61K 45/06 (2006.01);
U.S. Cl.
CPC ...
G01N 33/5023 (2013.01); A61K 31/192 (2013.01); A61K 31/38 (2013.01); A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/421 (2013.01); A61K 31/426 (2013.01); A61K 31/436 (2013.01); A61K 31/47 (2013.01); A61K 45/00 (2013.01); A61P 27/02 (2018.01); A61K 45/06 (2013.01); A61K 2300/00 (2013.01);
Abstract

The existent therapeutic drugs for CNV are merely pharmaceuticals for a symptomatic therapy, and therapeutic drugs for radical cure are strongly demanded. Also, a therapeutic drug for Dry AMD does not exist, and therapeutic drugs for radical cure are strongly demanded. The present invention provides a prophylactic and/or therapeutic agent for choroidal neovascularization, containing a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient. Also, the present invention provides a drusen suppressor comprising a compound having an activity of suppressing epithelial-mesenchymal transition in retinal pigment epithelial cells, as an active ingredient.


Find Patent Forward Citations

Loading…